Furthermore, the ZENITH20-2 study of poziotinib showed that the mPFS was 5.5 months and the ORR was 27% in advanced NSCLC patients with HER2 ex20ins (Elamin et al., 2021). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.